Sanofi promotes global head of diabetes to expand role

pharmafile | October 6, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi, biotech, diabetes, drugs, pharma, pharmaceutical 

Sanofi has promoted Stefan Oelrich to the position of Executive Vice President of Diabetes and Cardiovascular (DCV), giving him a position on the executive committee of the company. Oelrich had previously held the role as the global head of the diabetes franchise, as well as being the acting head of DCV in North America since July of this year.

Clearly, he had impressed with his handling of both businesses and his next job will be to solidify Sanofi’s position in DCV market – a particularly tricky task given how competitive the market is. It is a position that has already claimed two scalps in the last two years, with Peter Guenter leaving recently to become CEO at Almirall after he himself had replaced Pascale Witz in the role.

Oelrich arrives at the position having plenty of experience to draw upon, after arriving at Sanofi to take the position of General Manager of Germany, Switzerland and Austria. Prior to working at Sanofi, he had worked at Bayer and left the company after having risen to Senior Vice President & General Manager of Women’s Healthcare.

“Stefan is a highly effective leader who has demonstrated his ability to deliver strong results during his tenure at Sanofi,” said Olivier Brandicourt, Sanofi’s Chief Executive Officer. “As one of the architects of our Diabetes & Cardiovascular business unit, I am confident Stefan will succeed in driving our strategy forward in the coming years.” 

Sanofi noted that Oelrich will remain in charge of his previous position until successors are found to lead both divisions.

Related Content

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for …

Sanofi shares new data for long-term efficacy of Nexviazyme for Pompe disease treatment

Sanofi has shared new data for the long-term efficacy of Nexviazyme (avalglucosidease alfa) for the …

Janssen and Sanofi enter agreement for potential vaccine programme

Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with …

Latest content